Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel: Oncology Business Models Determined By Capital And Culture

This article was originally published in The Pink Sheet Daily

Executive Summary

Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.

You may also be interested in...



Astex Aims To Make Cancer Drug Resistance Futile

“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.

Exelixis Explains Virtues Of Flat Pricing For Cometriq

Approval in very rare medullary thyroid cancer marks an important milestone for Exelixis’ Cometriq (cabozantinib), which is being positioned for multiple cancers. The company will need only five sales reps for the thyroid cancer market and plans to launch in late January 2013 at the price of $9,900 per 28 days.

Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach

The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel